All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IPH6101
Therapeutic Area: Oncology Product Name: SAR443579
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $8.4 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2021
Details:
Sanofi has taken a decision on the progress of the IPH6101/SAR443579 investigational new drug enabling studies. Innate Pharma is eligible for up to €400m in development and commercial milestone payments as well as net sales royalties, under the terms of this collaboration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT-001
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: BioInvent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
BT-001 is a Vaccinia virus generated using Transgene’s Invir.IO™ platform and its large-capacity VVcopTK-RR- oncolytic virus, designed to encode a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s n-CoDeR®/F.I.R.S.T™, and a human GM-CSF cytokine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AB8939
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The therapeutic potential of AB8939 in AML is demonstrated using Ara-C resistant and azacitidine resistant patient-derived xenograft (PDX) models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BiCKI-IL-7
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The AACR update presentations show that BiCKI®-IL-7 will help overcome resistance mechanisms to anti-PD(L)-1 therapies and could potentially address the needs of a patient population in immune escape from checkpoint inhibitor treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-CLEC-1 monoclonal antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
OSE Immunotherapeutics’ poster presentation featured CLEC-1 antagonist monoclonal antibodies, which have been identified as an innovative immunotherapy that releases the brakes on macrophage phagocytosis and dendritic cells and demonstrates synergistic anti-cancer effects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
AACR abstract outlines the broad therapeutic potential of BT-001, an oncolytic virus encoding an anti-CTLA4 antibody.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STI-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Portage Biotech
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Financing May 11, 2020
Details:
Stimunity has reached a major milestone in its preclinical development plan and the additional financing will enable it to start the manufacturing of its biologic cGAMP-VLP (STI-001) lead compound.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Details:
Comprehensive data package supports pending clinical trial application for the first-in-human study of BT-001.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OX401
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABD-3001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Xerys Funds
Deal Size: $9.8 million Upfront Cash: Undisclosed
Deal Type: Funding February 26, 2020
Details:
Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
